GLAND PHARMA LIMITED

August 25, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Proceedings of the 48th Annual General Meeting of the Company

We hereby notify you that the 48th Annual General Meeting (AGM) of the Company was held on Tuesday, August 25, 2026 at 11:00 A.M. through Video Conferencing / Other Audio-Visual Means (OAVM).

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Speech & Presentation by Mr. Srinivas Sadu - Executive Chairman, enclosed as Annexure A
2. Proceedings of the AGM, enclosed as Annexure B

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.25 22:18:32 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: Annexures A & B

Annexure A

Forty-Eighth Annual General Meeting
Tuesday, 25th August 2026
Address by Mr. Srinivas Sadu – Executive Chairman

Good morning, ladies and gentlemen. On behalf of the board of directors of Gland Pharma Limited, I cordially invite each one of you to the 48th Annual General Meeting of the Company. This meeting is being conducted through video conferencing and other audio-visual mode. We comply with the regulatory requirements of Securities and Exchange Board of India.

The Company has taken all possible steps to ensure that the shareholders are provided with an opportunity to participate at the Annual General Meeting and also to vote. We are very much pleased to have your virtual presence here together with us today.

Presentation by the Executive Chairman

Good morning again, ladies and gentlemen. A very warm welcome to the 48th Annual General Meeting of Gland Pharma Limited. On behalf of the Board of Directors, the leadership team, and every member of the Gland Pharma family, I thank you for joining us today. It is my privilege to address you as Executive Chairman, and to walk you through a year of good performance and purposeful progress - a year that truly reflects our belief that this is a company *"where quality leads and capabilities enhance."*

Our Journey of Quality, Growth, and Value Creation

The foundations that make Gland Pharma the company it is today — a journey defined by quality, growth, and consistent value creation.

First, our manufacturing strength. We operate extensive and vertically integrated sterile injectable manufacturing capabilities, with a capacity of approximately 1.7 billion units per year across 11 manufacturing facilities - 8 formulation sites and 3 API sites. This vertical integration gives us greater control over our manufacturing processes, which is central to both our quality and our cost competitiveness.

Second, our compliance track record. Quality is a non-negotiable at Gland Pharma. We have maintained a strong regulatory compliance track record, reflected in no warning letters from the USFDA since the inception of each facility, and our sites are accredited by a wide range of global regulatory agencies.

Third, our diversified business model. We operate a diversified CDMO and B2B-led model across markets, with a successful track record of working with leading pharmaceutical companies, and we export to over 60 countries. Our CDMO engagements, in particular, give us strong long-term business visibility.

Fourth, the breadth of our portfolio. We offer a wide range of injectable products across therapeutic areas and delivery systems, including complex and in-licensed products. We have a pipeline of 24 complex and 15 co-development products.

And finally, our financial strength. Backed by strong financials, a healthy balance sheet and robust cash flow, our diversified revenue model continues to fuel growth and profitability.

These strengths, built patiently over four decades, are the bedrock on which our future growth will be delivered.

Strengthening Our Position Amid Global Shifts

The past year has once again tested the resilience of the global economy. It marked persistent macroeconomic headwinds, including geopolitical uncertainties and shifting trade dynamics. As per the IMF's April 2026 World Economic Outlook, global growth is projected at 3.1% in 2026, with a marginal improvement to 3.2% in 2027, reflecting a stable but below-trend expansion.

Yet, amid this uncertainty, our industry continues to show remarkable strength. The global pharmaceutical industry continues to demonstrate resilient growth, driven by rising healthcare demand, increasing prevalence of chronic diseases, broader access to medicines and continued innovation in specialty and complex therapies. These developments necessitate strategic agility and a firm commitment to cost discipline.

Against this backdrop, our positioning is a source of confidence. The Indian pharmaceutical sector continues to demonstrate remarkable strength, with Gland Pharma firmly positioned within it. The opportunity ahead is significant: the global injectable market is an area with sustained patent expiry opportunities, increasing adoption of biosimilar injectables and advancements in complex manufacturing and ready-to-use formulations. This is precisely the space where Gland Pharma is built to lead.

FY26 Performance: Strong Growth and Margin Expansion

I am delighted to share our performance for the fiscal year 2025-26 - a year of good growth and meaningful margin expansion.

For FY26, Gland Pharma delivered a consolidated revenue of ₹64,307 million and an EBITDA of ₹16,295 million, with a margin of 25%. This performance reflects a remarkable 275 basis points year-on-year improvement in the EBITDA margin. PAT rose 47% to ₹10,273 million, taking our PAT margin to 16%.

I am also pleased to report a decisive turnaround at Cenexi. Cenexi revenues grew by 25% to ₹18,693 million, leading to significant EBITDA improvement due to significant improvement in operational efficiencies. The strategic transformation we set in motion is now translating into tangible results, and Cenexi is steadily moving toward its rightful role as a value-accretive part of our platform.

Creating Sustainable Value Through ESG

At Gland Pharma, sustainability is not a parallel agenda — it is integral to how we operate. Our approach to Environmental, Social, and Governance reflects a deeply embedded philosophy that guides our actions, strengthens resilience, and supports long-term value creation. This year, I am pleased to share that our ESG commitments translated into measurable outcomes across each of the three pillars.

Environmental: Firstly, on the environmental side, we continued to accelerate our shift toward cleaner energy, with significant solar infrastructure investments at our manufacturing sites, while our water conservation initiatives, driven by technology upgrades, reflect a responsible stewardship of natural resources. These efforts delivered tangible results in FY26 — directed towards carbon optimisation, circular economy practices, and strengthening water and waste management. During the year, we conserved 5.79% in energy and recycled 51.03% of our water, underscoring the real progress behind our commitments.

Social: Second, on the social front, our efforts remain focused on creating a tangible, positive impact within the communities we serve, with projects spanning from enhancing school infrastructure to implementing various rural welfare programmes. We conducted 21 CSR projects, reaching more than 61,000 beneficiaries. These initiatives are deliberately structured for lasting impact — each programme is thoughtfully aligned with the United Nations Sustainable Development Goals, spanning educational empowerment, environmental protection and conservation, and healthcare and community well-being.

Governance: Third, on governance, we continue to maintain the highest standards of governance, which underpins our entire operation, ensuring that we operate with transparency, accountability, and integrity. Strong governance remains the foundation on which our environmental and social commitments — and the trust of all our stakeholders — securely rest.

Together, these outcomes demonstrate that as Gland Pharma grows, we ensure that growth progresses alongside environmental responsibility, supported by innovation, accountability and continuous improvement.

Six Strategic Levers for Future Growth

As we look ahead, our growth strategy is anchored on six clear strategic levers:

1. **Strengthening CDMO as a core growth engine** by expanding high-value CDMO partnerships across oncology, peptides, GLP-1 and complex injectables to drive growth and margin expansion.

2. **Widening our complex injectables and specialty portfolio** by building a differentiated portfolio comprising specialty injectables, liposomals and sophisticated drug delivery platforms.

3. **Investing in capacity expansion and manufacturing capabilities** by undertaking large-scale capacity additions and infrastructure ramp-up to support our future pipeline and rising global demand.

4. **Leveraging Cenexi as a strategic platform in Europe** by integrating Cenexi with Gland Pharma's operations to strengthen our footprint across Europe while unlocking cross-selling opportunities.

5. **Driving geographic expansion and market diversification** by widening our presence across regulated and emerging markets through deeper customer relationships, new launches and broader global market access.

6. **Advancing ESG and sustainable operations** by propelling sustainability through energy optimisation, operational efficiencies, responsible manufacturing practices and technology-led process improvements.

Strengthening Our Global Footprint

Let me now turn to how the growth played out across our markets -

1. The US remained a key growth engine, delivering consolidated revenue of ₹34,214 million, up 13% year-on-year. The portfolio was strengthened with the launch of 31 new molecules, reinforcing market leadership and deepening customer relationships.

2. Europe recorded a strong performance, contributing revenue of ₹14,035 million, a growth of 34%. Our other core markets, including Canada, Australia and New Zealand, achieved 12% year-on-year growth, driven by targeted execution and market-specific initiatives.

3. Our Rest of the World markets generated revenue of ₹11,117 million, reflecting continued geographic diversification, while our India business contributed ₹2,672 million.

Building a Scalable Innovation Platform

Underpinning the commercial success is a robust and scalable innovation platform.

- Our dedicated R&D centre in Hyderabad, complemented by on-site technical support across manufacturing locations, is powered by a team of over 250 scientists and professionals, including PhDs, pharmacy postgraduates, and experienced chemists. The depth and scale of our scientific expertise enable accelerated product development, efficient execution, and robust support for global regulatory submissions.

- Our cumulative ANDA filings now stand at 388 — of which 337 are approved and 51 are pending approval — and we now have 1,828 product registrations globally. Our capabilities span sterile injectables, with a focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings — across a broad range of delivery systems and therapeutic areas.

Advancing Our Complex Product Portfolio & Growth Pipeline

Our future growth is being built curatively, product by product, through a differentiated and high-barrier pipeline.

1. Six complex products were successfully launched, with three additional products progressing toward approval, reinforcing a key growth avenue and long-term value creation.

2. We have 15 products under co-development, comprising seven 505(b)(2) products and eight ANDAs, with commercialisation expected to commence from FY28.

3. We have 21 Ready-to-Use infusion bag products filed, with 18 approvals received to date and 11 additional products under development. This portfolio targets an addressable US market opportunity of approximately US$634 million.

4. During the year, we invested ₹2,230 million in R&D, supporting the filing of 24 new ANDAs. We have received 28 product approvals during the year

Our Strategic Roadmap

Everything I have shared today rests on six enduring strategic foundations that will guide our next phase of growth:

1. Achieve **Business Expansion** by scaling our business through product depth, customer expansion and geographic diversification.

2. **Expand R&D and Portfolio** by enhancing innovation capabilities to build a differentiated, scalable and future-ready portfolio.

3. **Foray into Complex CDMO, including Biologics** by strengthening our position in high-value CDMO and biologics through integrated capabilities and strategic collaborations.

4. Targeted **Strategic Acquisitions and Integration** to enhance capabilities, scale and market access.

5. **Augmenting Manufacturing Capacities and Capabilities** by enhancing manufacturing scale and technological capabilities.

6. **Elevating Our ESG Commitments** by integrating sustainability, governance and responsible practices across operations to drive long-term value

Building the Future with Confidence

As I come to the close of my address, I do so with genuine optimism about the journey ahead.

The years behind us have shaped an organisation that is resilient, purposeful and ready for what comes next. We have built something enduring — a company grounded in strong values, driven by talented people, and trusted by partners and stakeholders across the world. That is a foundation few can replicate, and it gives me great confidence in the road ahead.

The path before us is rich with possibility. As healthcare needs evolve and new opportunities emerge, we are well prepared to meet them — with clarity of purpose, disciplined execution, and a spirit of innovation that has always set us apart. We will keep pushing boundaries, keep raising our standards, and keep creating meaningful value for everyone we serve.

Above all, I want to express my heartfelt gratitude. To our employees, whose dedication is the heartbeat of this company; to our customers and partners, for their trust and collaboration; and to you, our shareholders, for your steadfast belief in our vision. It is your support that carries us forward.

Together, we will continue to build a brighter, healthier future — with confidence, with commitment, and with a shared sense of purpose.

Thank You

Thank you, once again, for your presence, your confidence and your continued partnership. As we move forward, we remain a company ***where quality leads and capabilities enhance***.

Thank you!!!

****

GLAND PHARMA LIMITED

Gland Pharma Limited

48th Annual General Meeting

Srinivas Sadu
Executive Chairman

25th August, 2026

Where Quality Leads and Capabilities Enhance

Our Journey of Quality, Growth, and Value Creation

GLAND PHARMA LIMITED

Extensive and Vertically Integrated Sterile Injectable Manufacturing Capabilities	Capacity ~ 1.7 Bn units/year 11 Manufacturing Facilities – 8 Formulations and 3 APIs	Greater Control Over Manufacturing Processes
Strong Compliance Track Record	No Warning Letters from USFDA Since Inception of Each Facility	USFDA, EMA, MHRA, BGV, ANVISA, TGA, MCC, WHO, DKMA, etc.
Diversified CDMO and B2B - led Model Across Markets	Successful Track Record of Operating CDMO and B2B Model with Leading Pharma Companies	Exports to Over 60 Countries Long-term business visibility with CDMO
Wide range of Product Portfolio, including Complex and In-licensed Products	Portfolio of Injectable Products Across Therapeutic Areas and Delivery Systems	388 ANDA Filings in the US(1)(2) : 337 Approved, 51 Pending Approval Pipeline: 24 Complex & 15 Co-Development, Team of ~250+ Personnel
Strong Financials, Healthy Balance Sheet, and Robust Cash Flow	Diversified Revenue Model Fuels Growth and Profitability	FY26A: Revenue: INR 64,307 Mn EBITDA Margin: 25%, PAT Margin: 16%

Note: (1) As of March 31, 2026; (2) Filed by Gland Pharma, along with partners

Strengthening Our Position Amid Global Shifts

GLAND PHARMA LIMITED

Global Economic Landscape

- The past year marked persistent macroeconomic headwinds, including geopolitical uncertainty and shifting trade dynamics.
- As per the IMF's April 2026 World Economic Outlook, global GDP growth is projected at 3.1% in 2026, with a marginal improvement to 3.2% in 2027, reflecting a stable but below-trend expansion.

Navigating Challenges

- The global pharmaceutical industry continues to demonstrate resilient growth, driven by rising healthcare demand, increasing prevalence of chronic diseases, broader access to medicines and continued innovation in specialty and complex therapies.
- These developments necessitate strategic agility and a firm commitment to cost discipline.

Our Strong Positioning

- The Indian pharmaceutical sector continues to demonstrate remarkable strength, with Gland Pharma firmly positioned within it.
- The global injectable market is an area with sustained patent expiry opportunities, increasing adoption of biosimilar injectables and advancements in complex manufacturing and ready-to-use formulations.

FY26 Performance: Strong Growth and Margin Expansion

GLAND PHARMA LIMITED

₹ Mn

Consolidated P&L			
Particulars	**FY26**	**FY25**	**YoY**
Revenue from operations	**64,307**	**56,165**	**14%**
Other Income	3,163	2,136	48%
Total Income	**67,470**	**58,301**	**16%**
Gross Profit	**41,877**	**35,261**	**19%**
Gross Profit margin (%)	*65%*	*63%*	
EBITDA	**16,295**	**12,689**	**28%**
EBITDA margin(%)	*25%*	*23%*	
PBT	**14,646**	**10,627**	**38%**
PBT margin(%)	*23%*	*19%*	
PAT	**10,273**	**6,985**	**47%**
PAT margin(%)	*16%*	*12%*	

Cenexi					
Particulars	**FY26**		**FY25**		**YoY**
	€ Mn.	**₹ Mn.**	**€ Mn.**	**₹ Mn.**	
Revenue from operations	182	18,693	164	14,916	25%
Gross Profit	**139**	**14,216**	**125**	**11,318**	**26%**
Gross Profit margin (%)	*76%*	*76%*	*76%*	*76%*	
EBITDA	**(3)**	**(336)**	**(19)**	**(1,761)**	
EBITDA margin(%)	*-2%*	*-2%*	*-12%*	*-12%*	

Financial Performance:

- For FY26, Gland Pharma delivered a consolidated revenue of **₹64,307 million** and an EBITDA of **₹16,295 million,** with a margin of **25%.**
- This performance reflects a remarkable 275 bps year-on-year improvement in the EBITDA margin.
- **Cenexi** revenues grew by 25% to **₹18,693 million,** leading to significant EBITDA improvement due to operational leverage.

Creating Sustainable Value Through ESG

GLAND PHARMA LIMITED

"Our approach to Environmental, Social, and Governance (ESG) reflects a deeply embedded philosophy that guides our actions, strengthens resilience, and supports long-term value creation."

Environmental

- A shift toward cleaner energy is being accelerated, with significant solar infrastructure investments at manufacturing sites.
- Water conservation initiatives, driven by technology upgrades, reflect a responsible stewardship of natural resources.

Social

- Efforts are focused on creating a tangible, positive impact within the communities served.
- Projects span from enhancing school infrastructure to implementing various rural welfare programs.

Governance

- The highest standards of governance are maintained, which underpins the entire operation.
- This ensures that the company operates with transparency, accountability, and integrity.

Six Strategic Levers for Future Growth

GLAND PHARMA LIMITED

1

Strengthening CDMO as a core growth engine:

- Expanding high-value CDMO partnerships across oncology, peptides, GLP-1 and complex injectables to drive growth and margin expansion.

2

Widening complex injectables and specialty portfolio:

- Building a differentiated portfolio comprising specialty injectables, liposomals and sophisticated drug delivery platforms.

3

Investing in capacity expansion and manufacturing capabilities:

- Undertaking large-scale capacity additions and manufacturing infrastructure ramp-up through sustained investments, supporting future pipeline and rising global demand.

4

Leveraging Cenexi as a strategic platform in Europe:

- Integrating Cenexi with Gland Pharma's operations to strengthen footprint across Europe while augmenting customer engagement and unlocking cross-selling opportunities

5

Driving geographic expansion and market diversification:

- Widening presence across regulated and emerging markets through deeper customer relationships, new launches and broader global market access.

6

Advancing ESG and sustainable operations:

- Propelling sustainability through energy optimisation, operational efficiencies, responsible manufacturing practices and technology-led process improvements.

Strengthening Our Global Footprint

GLAND PHARMA LIMITED

Consolidated Market-Wise Performance			₹ Mn
Particulars	**FY26**	**FY25**	**Y-o-Y**
USA	34,214	30,387	13%
Europe	14,035	10,470	34%
Canada, Australia & New Zealand *(Other Core Markets)*	2,269	2,021	12%
India	2,672	2,487	7%
Rest of the world	11,117	10,800	3%
TOTAL	**64,307**	**56,165**	**14%**



US Market:

- The **US remained a key growth engine,** delivering consolidated revenue of **₹34,214 million.**
- The portfolio was strengthened with the launch of **31 new molecules**, reinforcing market leadership and deepening relationships with customers.

Other Core Markets:

- **Europe recorded steady performance,** contributing revenue of **₹14,035 million.**
- Other core markets - including Canada, Australia and New Zealand - achieved **12% year-on-year growth,** driven by targeted execution and market-specific growth initiatives.

Emerging Markets:

- **Rest of the World (RoW) markets** generated revenue of **₹11,117 million,** reflecting continued geographic diversification.
- The **India business contributed ₹2,672 million,** supported by a focused approach to capturing emerging growth opportunities.

Building a Scalable Innovation Platform

Extensive Portfolio of Complex Products

Present in sterile injectables with a focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings

Delivery Systems:

- Liquid vials
- Lyophilized vials
- Pre-filled syringes
- Ampoules
- Bags
- Eye Drops
- Pens
- Cartridges

Therapeutic Areas:

- Anti-diabetic
- Anti-infectives
- Antimalarial
- Anti-neoplastic (Oncology)
- Blood-related
- Cardiac
- Gastrointestinal
- Hormonal products
- Neurological and Central Nervous System
- Ophthalmics and Ontologicals
- Pain, neuromuscular blocking agents & analgesics
- Respiratory and Pulmonology
- Vitamins, minerals & nutrients

R&D & Regulatory Capabilities

- Our dedicated R&D centre in Hyderabad, complemented by on-site technical support across manufacturing locations, is powered by a team of over 250 scientists and professionals, including PhDs, pharmacy postgraduates, and experienced chemists.
- The depth and scale of our scientific expertise enable accelerated product development, efficient execution, and robust support for global regulatory submissions.
- With capabilities spanning a broad spectrum of pharmaceutical research and a growing specialization in injectables, we are well positioned to bring high-quality products to market with speed and efficiency.

Regulatory Filing Status



Note: 1. ANDA count includes technology transfer ANDAs.

Advancing Our Complex Product Portfolio & Growth Pipeline

GLAND PHARMA LIMITED

Complex Product Strategy

- 6 complex products successfully launched, with 3 additional products progressing toward approval.
- Expanding pipeline of complex injectables reinforces a key growth avenue and supports long-term value creation.
- Continued focus on high-barrier, differentiated products to strengthen market positioning.

Co-development Portfolio

- 15 products under co-development, comprising 7 505(b)(2) products and 8 ANDAs.
- Commercialization expected to commence from FY28, creating a future growth pipeline.
- Strategic partnerships accelerate development and enhance portfolio breadth.

Ready-to-Use (RTU) Bags

- 21 RTU infusion bag products filed, with 18 approvals received to date.
- 11 additional RTU products under development, further expanding the portfolio.
- RTU portfolio targets an addressable US market opportunity of approximately US$634 million.

R&D Investments

- ₹2,230 million invested in R&D.
- Filed 24 new ANDAs and received 28 product approvals during the year.
- Cumulative ANDA filings reached 388, including 337 approvals and 51 pending approvals.
- Continued investment in innovation strengthens the pipeline and supports long-term growth objectives.

Our Strategic Roadmap

GLAND
GLAND PHARMA LIMITED

Business Expansion	• Driving growth by scaling our business through product depth, customer expansion and geographic diversification
R&D and Portfolio Expansion	• Enhancing innovation capabilities to build a differentiated, scalable and future-ready portfolio
Foray into Complex CDMO, including Biologics	• Strengthening position in high-value CDMO and biologics through integrated capabilities and strategic collaborations
Strategic Acquisitions and Integration	• Accelerating growth through targeted acquisitions that enhance capabilities, scale and market access
Augmenting Manufacturing Capacities and Capabilities	• Enhancing manufacturing scale and technological capabilities to support growth, efficiency and product complexity
Elevating Our ESG Commitments	• Integrating sustainability, governance and responsible practices across operations to drive long-term value

Building the Future with Confidence

GLAND PHARMA LIMITED

1

Vision

Guided by a clear purpose and strong strategic foundations, we are well positioned to navigate opportunities and challenges alike.

2

Innovation

Continuous innovation, prudent investments, and operational excellence enable us to strengthen our competitive advantage and drive growth.

3

Commitment

Our commitment remains unwavering: delivering quality, creating stakeholder value, and making a meaningful impact on global healthcare.

4

Gratitude

We thank our employees, customers, partners, and shareholders for their trust and contribution to our shared success.

GLAND PHARMA LIMITED

Where Quality Leads and Capabilities Enhance

Thank You

Annexure B

Summary of the proceedings of the 48th Annual General Meeting (AGM) of the members of Gland Pharma Limited ('the Company') held on Tuesday, 25 August 2026 at 11.00 A.M. (IST) through video conferencing (VC) facility/other audio-visual means (OAVM).

Directors Present through VC:

1.	Mr. Srinivas Sadu	Executive Chairman (participation from Corporate Office, Hyderabad)
2.	Ms. Naina Lal Kidwai	Independent Director (participation from Mumbai)
3.	Mr. Essaji Goolam Vahanvati	Independent Director (participation from Mumbai)
4.	Mr. Udo Johannes Vetter	Independent Director (participation from Germany)
5.	Mr. William Robert Keller	Independent Director (participation from Hongkong)
6.	Dr. Jia Ai Zhang	Director (participation from the United States of America)
7.	Mr. Wenjie Zhang	Director (participation from Beijing, China)
8.	Ms. Wei Huang	Director (participation from Shanghai, China)

In attendance through VC, participated from Hyderabad, India:

1.	Mr. Ravi Shekhar Mitra	Chief Financial Officer
2.	Mr. Sampath Kumar Pallerlamudi	Company Secretary & Compliance Officer

Other representatives through VC:

1. Mr. Sathya Pramod Koushik, Authorised representative of Ms. Monisha Parikh, Partner of M/s. Deloitte Haskins & Sells, Statutory Auditors, participated from Hyderabad, India

2. Ms. D Soumya, Scrutinizer and Secretarial Auditor, M/s RVR & Associates, Practising Company Secretaries, participated from Hyderabad, India

Members Present:

65 members (including speakers) attended the 48th Annual General Meeting through VC/OAVM.

Mr. Srinivas Sadu, Executive Chairman occupied the Chair and welcomed the members and corporate representatives to the Meeting. The quorum being present, the Meeting was called to order. The Chairman, then introduced the Directors to the shareholders.

Thereafter, Mr. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer informed the members that the Meeting is being conducted through video conference and webcast as per the provisions of the Companies Act, 2013 and various circulars issued by the MCA and SEBI.

He further stated that the Board's Report, Auditors' Report, Financial Statements for the FY 2025-26 and other reports along with Notice of the Meeting have already been circulated to the members at their registered e-mail ID. A letter containing a weblink and QR Code for accessing the Notice of 48th AGM and the Annual Report for the financial year 2025-26 has been sent to those members who have not registered their e-mail ID. He further informed that since there were no qualifications, observations, comments or remarks in the Statutory Auditor's report and the Secretarial Auditor's report for the year ended 31st March 2026; the reports of the Auditors were taken as read.

He also informed that the statutory documents, registers and reports as required to be maintained under the Companies Act, 2013 and all other documents referred to in the Notice which are required to be placed at the AGM for inspection by the members are open for inspection electronically.

The members were informed that the Company had provided the facility to cast their vote electronically, on all resolutions set forth in the Notice of the 48th AGM through remote e-voting provided by National Securities Depository Limited (NSDL). The remote e-voting facility was open from 9.00 AM (IST) on Saturday, August 22, 2026 and was closed at 5.00 PM on Monday, August 24, 2026.

The Company Secretary further informed the members that those members who attended the AGM and had not cast their votes through remote e-voting prior to the Meeting were provided an opportunity to cast their votes during the AGM through the e-voting facility provided by NSDL.

Thereafter, the Company Secretary invited the Chairman to address the shareholders and deliver his speech.

The Executive Chairman, Mr. Srinivas Sadu presented to the shareholders a brief overview of the journey of the Company and future business prospects such as Journey of Quality, Growth, and Value Creation; Strengthening Our Position Amid Global Shifts; Strong Growth and Margin Expansion; Creating Sustainable Value Through ESG; and further apprised on the Six Strategic Levers for future growth, etc.

Thereafter, with the permission of the Chairman, the Company Secretary explained the resolutions put forth to the shareholders for their approval. He stated that since the Meeting was held through VC and the resolutions provided in the Notice were being put to vote through e-voting, there would not be any proposing and seconding of the resolutions.

The resolutions put up for shareholder's approval were as under:

Ordinary Business(es):

1. To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Balance Sheet as at 31st March, 2026; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Reports of the Board of Directors and Auditors thereon.

2. To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Consolidated Balance Sheet as at 31st March, 2026; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereon.

3. To declare the final dividend on equity shares for the financial year ended 31st March 2026.

4. To reappoint Mr. Wenjie Zhang as a Director, liable to retire by rotation and being eligible offers himself for reappointment.

5. To reappoint Ms. Wei Huang as a Director, liable to retire by rotation and being eligible offers herself for reappointment.

All the aforementioned Resolutions were proposed as Ordinary resolutions.

Thereafter, queries were invited from the shareholders. The queries posed by the shareholders were suitably responded by Mr. Srinivas Sadu, Executive Chairman and Mr. Ravi Shekhar Mitra, CFO.

The Chairman announced for voting to be taken electronically (e-voting) and requested Ms. D Soumya, the scrutinizer for the orderly conduct of the e-voting.

The Chairman authorized the Company Secretary to receive the scrutinizer's report along with the consolidated report of voting and to announce the combined e-voting results and intimate the stock exchanges within two working days of the conclusion of the meeting. The scrutinizer's report along with the consolidated report of voting will also be made available on the website of the Company at www.glandpharma.com.

The Chairman thanked the shareholders for attending the 48th AGM of the Company and declared the Meeting as concluded at 12:30 P.M. (including 30 minutes time allowed for e-voting during AGM).

For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.25 22:19:39 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer